• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Indaptus Therapeutics Inc.

    8/12/24 8:16:09 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDP alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on August 12, 2024

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form S-8

    Registration Statement

    Under

    The Securities Act of 1933

     

    Indaptus Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   86-3158720

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

         

    3 Columbus Circle

    15th Floor

    New York, New York

      10019
    (Address of Principal Executive Offices)   (Zip Code)

     

    Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan

    (Full title of the plan)

     

    Jeffrey A. Meckler

    Chief Executive Officer

    Indaptus Therapeutics, Inc.

    3 Columbus Circle

    15th Floor

    New York, New York 10019

    (646) 427-2727

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    With copies to:

    Peter N. Handrinos, Esq.

    Latham & Watkins LLP

    John Hancock Tower

    200 Clarendon Street

    Boston, MA 02116

    (617) 948-6060

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☐
             

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,500,000 shares of the Registrant’s common stock that are or may become available for issuance under the Indaptus Therapeutics, Inc. 2021 Equity Incentive Plan (the “Incentive Plan”), as amended and restated effective June 6, 2024. Registration Statements of the Registrant on Form S-8 relating to the Incentive Plan are effective.

     

    INCORPORATION BY REFERENCE OF

    CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8

     

    The contents of the Registration Statements on Form S-8 (File Nos. 333-259127 and 333-270828), including any amendments thereto, filed with the Securities and Exchange Commission (the “SEC”), relating to the Incentive Plan, are incorporated herein by reference.

     

    Item 8. Exhibits

     

    Exhibit Number   Description
         

    4.1

      Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2021)
         
    4.2   Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of January 22, 2024 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 23, 2024)
         

    4.3

      Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2021)
         
    5.1*   Opinion of Latham & Watkins LLP
         
    23.1*   Consent of Haskell & White LLP, Independent Registered Public Accounting Firm
         
    23.2*   Consent of Latham & Watkins LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included on signature page)
         
    99.1   Indaptus Therapeutics, Inc. Amended and Restated 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on June 7, 2024)
         
    107.1*   Filing fee Table

     

    * Filed herewith.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York on August 12, 2024.

     

      INDAPTUS THERAPEUTICS, INC.
         
      By: /s/ Jeffrey A. Meckler
      Name: Jeffrey A. Meckler
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Jeffrey A. Meckler and Nir Sassi, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Jeffrey A. Meckler   Chief Executive Officer and Director   August 12, 2024
    Jeffrey A. Meckler   (principal executive officer)    
             
    /s/ Nir Sassi   Chief Financial Officer   August 12, 2024
    Nir Sassi   (principal financial and accounting officer)    
             
    /s/ Michael J. Newman   Chief Scientific Officer and Director   August 12, 2024
    Michael J. Newman, Ph.D.        
             
    /s/ Roger J. Pomerantz, M.D.   Chairman of the Board of Directors   August 12, 2024
    Roger J. Pomerantz, M.D.        
             
    /s/ Mark J. Gilbert   Director   August 12, 2024
    Mark J. Gilbert        
             
    /s/ William B. Hayes   Director   August 12, 2024
    William B. Hayes        
             
    /s/ Hila Karah   Director   August 12, 2024
    Hila Karah        
             
    /s/ Anthony J. Maddaluna   Director   August 12, 2024
    Anthony J. Maddaluna        
             
    /s/ Robert E. Martell, M.D., Ph.D.   Director   August 12, 2024
    Robert E. Martell, M.D., Ph.D.        

     

     

     

    Get the next $INDP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INDP

    DatePrice TargetRatingAnalyst
    1/31/2022$15.00Buy
    HC Wainwright & Co.
    10/19/2021$16.00Hold → Buy
    Maxim Group
    More analyst ratings

    $INDP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus' Co-Chief Executive Officer and Chairman of the Board. Jeffrey Meckler will continue as Co-CEO and remain on the Board. "In making this significant investment in Indaptus, I look forward to continuing to evaluate the Company's lead product cand

    12/29/25 7:00:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

    NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that Michael Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 3rd Donor Selection & Cell Source Summit, taking place November 19–20, 2025, in San Diego, California. Dr. Newman's presentation, titled, "Creating Super Donor Cells Post-Donation – Using Attenuated and Killed Bacteria to Induce, Polarize, and Activate Human Innate and Adaptive Immune Cells In Vitro," will highlight new research demonstrating how the Company's De

    11/17/25 8:00:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab. Following efficacy evaluations, three participants achieved stable disease at the first assessment, two of whom remain on study, while three parti

    11/12/25 8:30:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. resumed coverage on Indaptus Therapeutics with a new price target

    HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00

    1/31/22 7:21:10 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics upgraded by Maxim Group with a new price target

    Maxim Group upgraded Indaptus Therapeutics from Hold to Buy and set a new price target of $16.00

    10/19/21 8:57:59 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ben-Tzvi Avraham was granted 25,000 shares, increasing direct ownership by 25,000% to 25,100 units (SEC Form 4)

    4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    1/22/26 9:57:06 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Natan David

    4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    1/22/26 9:56:24 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Natan David claimed no ownership of stock in the company (SEC Form 3)

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    1/12/26 4:05:07 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDP
    SEC Filings

    View All

    SEC Form DEF 14A filed by Indaptus Therapeutics Inc.

    DEF 14A - Indaptus Therapeutics, Inc. (0001857044) (Filer)

    1/21/26 5:21:02 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

    1/20/26 4:06:48 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

    1/8/26 5:26:25 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDP
    Financials

    Live finance-specific insights

    View All

    Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the second quarter ended June 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "This quarter marks a major clinical inflection point for Indaptus. In under four years since our founding, we have progressed from IND-enabling studies to an active combination trial in patients. This pace of development is a testament to the dedication of the small, but focused

    8/13/25 8:00:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

    Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectationsEarly signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, "We continue

    3/13/25 7:30:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

    Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced a clinical supply agreement with BeiGene. Building on Indaptus' preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete

    10/22/24 8:00:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

    SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    11/26/24 4:11:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Indaptus Therapeutics Inc.

    SC 13D - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    10/10/24 4:10:11 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Indaptus Therapeutics Inc. (Amendment)

    SC 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    7/7/22 7:40:12 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INDP
    Leadership Updates

    Live Leadership Updates

    View All

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

    NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune sy

    2/8/24 8:00:00 AM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors.  As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mech

    11/6/23 4:01:00 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care